Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer

Phase I study of bicalutamide (Casodex), a nonsteroidal antiandrogen in patients with prostatic cancer

A phase I study (open trial) of bicalutamide (Casodex), a non-steroidal antiandrogen, was conducted on 16 patients with prostatic cancer (stage C to D). The patients were given 10, 30, 50, 80 or 100 mg of bicalutamide orally daily for 12 weeks. Adverse reactions were observed in 8 out of 16 patients...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 42(1996), 2 vom: 23. Feb., Seite 143-53
1. Verfasser: Kotake, T (VerfasserIn)
Weitere Verfasser: Usami, M, Isaka, S, Shimazaki, J, Oishi, K, Yoshida, O, Ozono, S, Okajima, E, Kanetake, H, Saitoh, Y, Tsukagoshi, S, Akaza, H, Koiso, K, Kameyama, S, Honma, Y, Aso, Y, Nakano, E, Okuyama, A, Naito, S, Kumazawa, J, Niitani, H, Taguchi, T
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1996
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial Clinical Trial, Phase I Controlled Clinical Trial English Abstract Journal Article Multicenter Study Androgen Antagonists Anilides Antineoplastic Agents Nitriles mehr... Tosyl Compounds bicalutamide A0Z3NAU9DP